STOCK MARKET BSE NSE

Emergency Use Listing nod to Covaxin expands availability of Covid vaccines: WHO official

Published: 03rd November 2021 06:55 PM  |   Last Updated: 03rd November 2021 06:55 PM   |  A+A-

A health worker displays empty vials of COVAXIN at a vaccination center. (Photo | AP)

By PTI

UNITED NATIONS/GENEVA: The Emergency Use Listing nod to Bharat Biotech's Covaxin, which was found to have 78% efficacy against severe cases, expands the availability of vaccines - the most effective medical tools to end the COVID-19 pandemic, a top World Health Organization official said on Wednesday.

On Wednesday, WHO issued an emergency use listing (EUL) for Covaxin, adding to a growing portfolio of vaccines validated by the UN health agency for the prevention of COVID-19 caused by SARS-CoV-2.

"This emergency use listing expands the availability of vaccines, the most effective medical tools we have to end the pandemic," said Dr Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products.

"But we must keep up the pressure to meet the needs of all populations, giving priority to the at-risk groups who are still waiting for their first dose, before we can start declaring victory."

WHO's EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for COVAX vaccine supply.

It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

​ALSO READ | Covaxin gets shelf life extension up to 12 months

"Congratulations India for Emergency Use Listing of its indigenously produced #COVID19 vaccine COVAXIN," WHO South East Asia Regional Director Poonam Khetrapal Singh said in a tweet.

Covaxin was assessed under the WHO EUL procedure based on the review of data on quality, safety, efficacy, a risk management plan and programmatic suitability.

The Technical Advisory Group (TAG), convened by WHO and made up of regulatory experts from around the world, has determined that the vaccine meets WHO standards for protection against COVID-19, that the benefit of the vaccine far outweighs risks and the vaccine can be used globally, WHO said.

The Bharat Biotech's vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.

ALSO READ | Doctors welcome expert panel's suggestion on Covaxin for children; flag issue of global acceptance

Covaxin was also reviewed on October 5 by WHO's Strategic Advisory Group of Experts on Immunization (SAGE), which formulates vaccine specific policies and recommendations for vaccines' use in populations (i.e.recommended age groups, intervals between doses, specific groups such as pregnant and lactating women).

The SAGE recommended use of the vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above.

Covaxin was found to have 78% efficacy against COVID-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements.

Available data on vaccination of pregnant women with the vaccine are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned, including a pregnancy sub-study and a pregnancy registry, WHO said.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

edexworks
flipboard facebook twitter whatsapp